Analysts Issue Forecasts for DNLI FY2025 Earnings

Key Points

• Cantor Fitzgerald has lowered its forecast for Denali Therapeutics' FY2025 earnings per share from ($2.97) to ($3.01), while the consensus estimate is ($2.71) per share.
• Denali Therapeutics reported a quarterly earnings per share of ($0.72), exceeding analysts' expectations of ($0.74), despite a year-on-year decline from ($0.59) EPS.
• Insider trading showed CEO Ryan J. Watts sold 495,282 shares at an average price of $15.00, resulting in a 66.18% reduction in his ownership of the stock.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Denali Therapeutics in a research note issued on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($3.01) per share for the year, down from their previous estimate of ($2.97). The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Cantor Fitzgerald also issued estimates for Denali Therapeutics' FY2026 earnings at ($3.26) EPS.

Several other analysts also recently commented on DNLI. Wedbush cut their target price on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright dropped their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Morgan Stanley cut their price target on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Stock Down 0.9%

NASDAQ:DNLI traded down $0.14 during trading hours on Thursday, reaching $14.68. 472,452 shares of the company traded hands, compared to its average volume of 1,406,595. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $33.33. The stock has a market capitalization of $2.15 billion, a P/E ratio of -5.24 and a beta of 1.36. The business's 50-day moving average price is $14.30 and its two-hundred day moving average price is $15.19. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same quarter in the prior year, the business earned ($0.59) earnings per share.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company's stock worth $79,000 after acquiring an additional 753 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Denali Therapeutics by 7.4% in the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company's stock valued at $189,000 after acquiring an additional 930 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its stake in Denali Therapeutics by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock worth $548,000 after purchasing an additional 1,058 shares during the last quarter. Sterling Capital Management LLC boosted its stake in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Denali Therapeutics by 12.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company's stock worth $190,000 after acquiring an additional 1,543 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares of the company's stock, valued at $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carole Ho sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider owned 217,391 shares in the company, valued at approximately $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock valued at $7,520,799 in the last three months. Company insiders own 12.50% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.